Study of URC102 to Assess the Safety and Efficacy in Gout Patients

JW Pharmaceutical

Status and phase: Completed; Phase 2

Conditions: Hyperuricemia; Gout

Treatments: Drug: Placebo; Drug: URC102

Study type: Interventional

Funder types: Industry

Identifiers

NCT02557126

URC103KR

Details and patient eligibility

About

The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.

Enrollment: 76 patients

Sex: Male

Ages: 20 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with gout

Exclusion criteria

• Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

76 participants in 2 patient groups, including a placebo group

URC102

Experimental group

Description:

URC102

Treatment:

Drug: URC102

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo